Monash IVF Group Ltd
ASX:MVF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Monash IVF Group Ltd
ASX:MVF
|
AU |
|
Cybrid Technologies Inc
SSE:603212
|
CN |
|
Applied Visual Sciences Inc
OTC:APVS
|
US |
|
Mesa Air Group Inc
NASDAQ:MESA
|
US |
|
Adacel Technologies Ltd
ASX:ADA
|
AU |
|
C
|
CodeNature Inc
KOSDAQ:078940
|
KR |
|
B
|
BinhThanh Import Export Production and Trade JSC
VN:GIL
|
VN |
Monash IVF Group Ltd
Monash IVF Group Ltd. engages in the field of fertility services. The company is headquartered in Richmond, Victoria and currently employs 669 full-time employees. The company went IPO on 2014-06-26. The firm also provides specialist women’s imaging services in Australia. The company operates through two segments, Monash IVF Group Australia and Monash IVF Group International. The Monash IVF Group Australia segment provides assisted reproductive services, ultrasound, and other related services. The Monash IVF Group International segment provides assisted reproductive services in Malaysia. The firm's business includes Fertility Solutions that provides fertility treatment and care; KL Fertility is a fertility specialist centre; Monash IVF is a fertility research and treatment center; Monash IVF KPJ Johor is a full-service hospital-based fertility centre; Monash Ultrasound for Women provides tertiary level prenatal diagnostic services; and Reproductive Medicine Albury is a provider of fertility treatments including In-vitro fertilization (IVF).
Monash IVF Group Ltd. engages in the field of fertility services. The company is headquartered in Richmond, Victoria and currently employs 669 full-time employees. The company went IPO on 2014-06-26. The firm also provides specialist women’s imaging services in Australia. The company operates through two segments, Monash IVF Group Australia and Monash IVF Group International. The Monash IVF Group Australia segment provides assisted reproductive services, ultrasound, and other related services. The Monash IVF Group International segment provides assisted reproductive services in Malaysia. The firm's business includes Fertility Solutions that provides fertility treatment and care; KL Fertility is a fertility specialist centre; Monash IVF is a fertility research and treatment center; Monash IVF KPJ Johor is a full-service hospital-based fertility centre; Monash Ultrasound for Women provides tertiary level prenatal diagnostic services; and Reproductive Medicine Albury is a provider of fertility treatments including In-vitro fertilization (IVF).
Earnings: Underlying NPAT of $10.4 million for H1 FY'26, delivered at the upper end of the AGM guidance range and underlying EBITDA of $30.2 million (22% margin).
Revenue: Group revenue was $137.9 million, down 1.8% vs prior comparable period; group stimulated cycles fell to 5,862, down 9.9%.
Guidance: FY'26 underlying NPAT guidance reiterated at $20 million and an interim fully franked dividend of $0.012 per share declared.
Margins & costs: EBITDA margin declined 3.5 percentage points, attributed to weaker volumes, legal/compliance costs, wage inflation and investment in clinical governance; management is targeting margin recovery through revenue and cost initiatives.
Clinical performance: Pregnancy rate per embryo transferred improved to 40.7% (up 0.6 percentage points year-on-year) and 49% for women under 35, which management highlights as a competitive strength.
Genetics & innovation: Genetics volumes and conversion indicators are strong (PGT-A up 31%, PGTM up 26%, PGTM cycle conversion up 25%); wearable hormone and other R&D programs progressing.
Regional performance: Asia business growing (Singapore stimulated cycles +6.4%, Johor Bahru +26%, KL revenue per cycle +7%); domestic market share declined to 19% (down 2.5ppt) with NSW and Victoria soft.
Leadership & strategy: New CEO outlined a focus on stabilizing operations, rightsizing costs, enhancing patient experience, strengthening medical leadership and completing final major clinic CapEx (Brisbane opening Q4 FY'26).
